Vonoprazan belongs to the potassium-competitive acid blocker class. It inhibits the H+/K+-ATPase in gastric parietal cells, blocking the final step of gastric acid secretion and providing potent, sustained acid suppression.
How it works
Who may be prescribed this medicine
Research and clinical evidence
Vonoprazan has been evaluated in clinical studies as an alternative to traditional proton pump inhibitors. Clinical evidence supports its ability to provide potent and sustained gastric acid suppression. Vonoprazan received its initial U.S. FDA approval in 2022. Current U.S. labeling includes healing and maintenance of healing of erosive esophagitis, relief of heartburn associated with non-erosive GERD, and combination treatment for H. pylori infection.
Dr. Reddy’s identifies vonoprazan as part of its gastrointestinal portfolio and lists oral tablet strengths of 10 mg and 20 mg. The company describes the active ingredient as providing rapid onset and sustained acid suppression.
Vonoprazan is used to reduce gastric acid production in acid-related gastrointestinal disorders.
Indications include:
Vonoprazan works by inhibiting the H+/K+-ATPase in gastric parietal cells, thereby reducing gastric acid secretion.
Take orally as directed by a healthcare professional. The tablet should be swallowed whole and should not be chewed or crushed. It may be taken with or without food. The appropriate dose and treatment duration depend on the indication, treatment regimen, and individual patient factors. When used for H. pylori eradication, vonoprazan should be taken only as part of the combination regimen prescribed by a healthcare professional.
Side Effects
Seek medical attention if severe, persistent, or unusual symptoms occur.
